2’3’-c-di-AM (PS) 2 (Rp, Rp)
2’3’-c-di-AM (PS) 2 (Rp, Rp) (ADU-S100), an activator of stimulator of interferon genes (STING), leads to potent and systemic tumor regression and immunity[1].
Product Specifications
CAS Number
[1638241-89-0]
Product Name Alternative
ADU-S100; MIW815; ML RR-S2 CDA
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
STING
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/2-3-c-di-am-ps-2-rp-rp.html
Purity
99.85
Solubility
H2O : 20 mg/mL (ultrasonic)
Smiles
O[C@H]1[C@@H](O[P@@](OC[C@H]2O[C@@H](N3C(N=CN=C4N)=C4N=C3)[C@H](O)[C@@H]2O5)(S)=O)[C@H](N6C(N=CN=C7N)=C7N=C6)O[C@@H]1CO[P@]5(S)=O
Molecular Formula
C20H24N10O10P2S2
Molecular Weight
690.54
Precautions
H302, H315, H319, H335
References & Citations
[1]Corrales L, et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015 May 19;11 (7) :1018-30.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture and light)
Badge
Hot
Scientific Category
Reference compound1
Clinical Information
Phase 2
Citation 01
ACS Appl Mater Interfaces. 2025 Feb 5;17 (5) :7395-7405.|ACS Appl Mater Interfaces. 2025 Oct 15;17 (41) :56832-56845.|Acta Crystallogr D Struct Biol. 2020 Sep 1;76 (Pt 9) :889-898. |Adv Funct Mater. 2025 Nov 11.|bioRxiv. 2024 May 14.|Cancer Cell. 2023 Jun 12;41 (6) :1073-1090.e12.|Cancer Res Commun. 2024 Jan 16;4 (1) :118-133.|Cell Biol Toxicol. 2025 May 7;41 (1) :82.|Cell Commun Signal. 2025 Feb 19;23 (1) :99.|Cell Mol Gastroenterol Hepatol. 2021;12 (1) :41-58.|Cell Mol Immunol. 2025 Dec;22 (12) :1549-1566.|Cell Signal. 2025 Jun 16:111948.|Environ Int. 2020 Oct;143:105949.|Eur J Med Chem. 2023 Mar 15:250:115184.|Front Immunol. 2021 Jul 1:12:695056.|Front Immunol. 2023 Oct 13:14:1258691.|Immunology. 2022 Dec;167 (4) :495-507.|Inflamm Res. 2023 Aug;72 (8) :1551-1565.|Int J Mol Sci. 2023 Dec 20;25 (1) :86.|J Control Release. 2025 Jan 14:379:327-343.|J Immunother Cancer. 2019 Sep 18;7 (1) :252. |J Neuroinflammation. 2023 Apr 30;20 (1) :101.|J Pharm Sci. 2025 Nov 17:104065.|Mol Cell Biochem. 2021 Feb;476 (2) :1015-1024.|Nat Commun. 2023 Mar 13;14 (1) :1390.|Nat Commun. 2023 Sep 18;14 (1) :5666.|Nat Commun. 2024 Nov 15;15 (1) :9934.|Nat Immunol. 2025 Oct;26 (10) :1766-1780.|Nat Nanotechnol. 2021 Nov;16 (11) :1260-1270.|Neuron. 2023 Jan 18;111 (2) :236-255.e7.|Oncoimmunology. 2025 Dec;14 (1) :2466305.|Patent. US20200146975A1|Patent. US20210205468A1.|Patent. US20230062932A1.|Patent. US20250221932A1.|Patent. US20250276085A1.|Purdue University. 2024 Jul 20.|Research Square Preprint. 2022 Feb.|Research Square Preprint. 2022 Jan.|Research Square Preprint. 2024 Apr 5.|University of Toronto. 2023 Jun.|Wayne State University. 2024.|Acta Pharm Sin B. 2025 Mar;15 (3) :1211-1229.|Adv Sci (Weinh) . 2024 Nov 19:e2407222.|Adv Sci (Weinh) . 2025 Apr;12 (16) :e2414110.|bioRxiv. 2024 September 07.|Cancer Cell. 2024 May 13;42 (5) :850-868.e9.|Cell Death Dis. 2022 Jul 28;13 (7) :653.|Cell Rep Med. 2025 Jul 15;6 (7) :102239.|Chem Biodivers. 2024 Jul 12:e202401253.|Genes Dis. 2024 Sep 15;12 (2) :101434.|J Autoimmun. 2024 Jun:146:103232.|J Immunother Cancer. 2024 Oct 14;12 (10) :e009803.|Mol Ther. 2025 Sep 22:S1525-0016 (25) 00761-0.|Nat Cell Biol. 2024 Sep;26 (9) :1585-1596.|Nat Commun. 2023 Oct 2;14 (1) :6132.|Sci China Life Sci. 2024 Dec;67 (12) :2664-2677.|Biomaterials. 2018 May;163:67-75. |bioRxiv. 2024 Jan 23.|bioRxiv. 2024 September 20.|bioRxiv. October 23, 2021.|Cancer Cell. 2020 Mar 16;37 (3) :289-307.e9. |Commun Biol. 2021 Apr 22;4 (1) :497.|Eur J Med Chem. 2022 Dec 5:243:114796.|J Clin Invest. 2024 Mar 19;134 (10) :e176748.|J Interferon Cytokine Res. 2025 Jan;45 (1) :29-37.|Mater Today Bio. 2024 Mar 11:26:101018.|Nat Commun. 2022 May 31;13 (1) :3022.|Nature. 2023 Apr;616 (7958) :806-813.|Patent. US20210322327A1.|Patent. US20220162199A1.|Patent. US20220395465A1.|PLoS One. 2020 Sep 10;15 (9) :e0237743.|University of Pittsburgh. School of Medicine. 2021 May 14.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1394381-01 0.02 mg (E-Coli)
Recombinant Vibrio parahaemolyticus Urease accessory protein UreG (ureG)
Ask
View Details 
MBS1394381-02 0.1 mg (E-Coli)
Recombinant Vibrio parahaemolyticus Urease accessory protein UreG (ureG)
Ask
View Details MBS1394381-03 0.02 mg (Yeast)
Recombinant Vibrio parahaemolyticus Urease accessory protein UreG (ureG)
Ask
View Details